Status:
ACTIVE_NOT_RECRUITING
A Clinical Study to Assess the Efficacy of Cannabigerol in Patients with Active Rheumatoid Arthritis.
Lead Sponsor:
Raphael Pharma
Collaborating Sponsors:
Citruslabs
Conditions:
Rheumatoid Arthritis
Inflammatory Disease
Eligibility:
All Genders
25+ years
Phase:
NA
Brief Summary
This is a single-group exploratory longitudinal prospective study lasting 8 weeks. The study aims to measure the efficacy of purified cannabigerol (CBG) in patients with active rheumatoid arthritis us...
Eligibility Criteria
Inclusion
- Male or female, over 25 years of age
- Positive anti-CCP blood test
- Active RA-related inflammation with at least 2 swollen joints
- University graduate
- Generally healthy with no uncontrolled chronic disease
- Able to read, understand, and sign informed consent
- Resides in the USA
- Willing to comply with study requirements and avoid other cannabis products during the study period
Exclusion
- Pre-existing chronic conditions preventing adherence
- Severe allergic reactions requiring an Epi-pen
- Use of opiates in the last 4 weeks or cannabis in the last 8 weeks
- Pregnant or breastfeeding women
- Recent invasive medical procedure or surgery
- Active malignancy or ongoing oncology treatment
- Use of cytochrome P450 or 3A4 inhibitors
- History of substance abuse
Key Trial Info
Start Date :
June 3 2024
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2024
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT06513507
Start Date
June 3 2024
End Date
December 31 2024
Last Update
November 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Citruslabs
Santa Monica, California, United States, 90404